View ValuationTecan Group 향후 성장Future 기준 점검 3/6Tecan Group (는) 각각 연간 51.7% 및 4.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 49.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.7% 로 예상됩니다.핵심 정보51.7%이익 성장률49.51%EPS 성장률Life Sciences 이익 성장16.9%매출 성장률4.6%향후 자기자본이익률8.71%애널리스트 커버리지Good마지막 업데이트02 May 2026최근 향후 성장 업데이트공지 • Oct 13Tecan Reaffirms Earnings Guidance for the Year 2025Tecan reaffirmed earnings guidance for the year 2025. For the year, Tecan confirmed its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range. Tecan also reiterates its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. However, end markets are expected to recover gradually, so a full normalization is not anticipated in 2026. Guidance for 2026 will be provided, as usual, with the full-year 2025 results in March 2026.공지 • Aug 13+ 1 more updateTecan Group AG Revises Earnings Guidance for the Year 2024Tecan Group AG revised earnings guidance for the year 2024. Based on the financial results from the first half of the year, Tecan has revised its full-year outlook. This revision is also due to the anticipation that weaker demand, driven by general market weakness, will persist longer than originally expected, while the new China stimulus program is likely to have a meaningful impact only from 2025. The company now expects full-year 2024 sales in local currencies to range from on prior-year level to a decrease in the mid single-digit percentage range (previously expected to increase in the low single-digit percentage range in local currencies).공지 • Mar 14+ 1 more updateTecan Group AG Provides Earnings Guidance for the Year 2024Tecan Group AG provided earnings guidance for the year 2024. For the year, the company expects Sales growth expected in the low single-digit percentage range in local currencies.공지 • Aug 17Tecan Group AG Provides Earnings Guidance for the Full Year 2023Tecan Group AG provided earnings guidance for the full year 2023. For the year, the company continues to forecast sales to increase in the low to mid single-digit percentage range in local currencies. This expectation includes the negative impact of lower COVID-related sales (approximately -4% points for the full year 2023, with the largest share of the impact already recorded in the first half of the year) and the reduced pass-through of material costs (at least -1% point). Underlying sales, which exclude these negative effects, are expected to grow in the high single-digit percentage range in local currencies.모든 업데이트 보기Recent updates공지 • Apr 16Tecan Group Ag Announces Executive ChangesTecan Group AG in its AGM meeting held on April 15, 2026, announced that shareholders elected three new members of the Board of Directors: Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot. Matthias Gillner, who has been a member of the Board of Directors since 2023 and its Vice-Chairman, was elected as the new Chairman. He will step down as Chair of the Audit Committee but will remain a member, alongside Guillaume Daniellot and Gitte Pugholm Aabo. With the addition of the newly elected members, the Board of Directors will once again comprise seven members, ensuring an optimal balance of expertise, skills, and experience for the future. Lukas Braunschweiler, Chairman and a member of the Board since 2018, did not stand for re-election.공지 • Mar 30The Tecan Group Announces the Appointment of Camila Japur as Chief Financial Officer, Effective on June 1, 2026The Tecan Group announced the appointment of Camila Japur as Chief Financial Officer, who will join the company on June 1, 2026. Camila currently serves as Group CFO of u-blox, where she has successfully led transformation initiatives, driving cost efficiency, strengthening financial processes, and enhancing capital market engagement. Prior to this, Camila spent 24 years at Ericsson, including seven years as CFO for the Enterprise Segment. Camila has an MBA from Fundação Getulio Vargas in São Paulo and a Bachelor's Degree in Economics from Universidade Mackenzie in São Paulo.공지 • Mar 25Tecan Group AG Announces Member of the Board of Directors Oliver Fetzer Will Not Stand for Re-ElectionTecan Group AG announced that Oliver Fetzer, a member of the Board since 2011, has decided not to stand for re-election at the AGM to be held on April 15, 2026.공지 • Mar 16+ 1 more updateTecan Group AG Proposes Dividend for the Full Year 2025The Board of Directors of Tecan Group AG will propose an unchanged dividend of CHF 3.00 per share at the Annual General Meeting on April 15, 2026 for the full year 2025. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.공지 • Dec 19Tecan Group AG to Report First Half, 2026 Results on Aug 11, 2026Tecan Group AG announced that they will report first half, 2026 results on Aug 11, 2026공지 • Dec 05Tecan Group AG, Annual General Meeting, Apr 15, 2026Tecan Group AG, Annual General Meeting, Apr 15, 2026.공지 • Dec 04ecan Group AG Announces Chairman of the Board of Directors Lukas Braunschweiler Will Not Stand for Re-ElectionTecan Group AG announced that Lukas Braunschweiler, Chairman of the Board of Directors and a member of the Board since 2018, will not stand for re-election.공지 • Dec 02Tecan Group AG (SWX:TECN) acquired Wako Automation.Tecan Group AG (SWX:TECN) acquired Wako Automation on December 1, 2025. Tecan Group AG (SWX:TECN) completed the acquisition of Wako Automation on December 1, 2025.공지 • Nov 17+ 1 more updateTecan Group AG Announces Departure of Tania Micki as Member of the Management BoardTecan Group AG announced that Tania Micki, member of the Management Board since February 2020, will be leaving the company to pursue an external opportunity. She will continue in her role through May 2026 to ensure a smooth transition. Tecan will nominate her successor in due time, leveraging the company’s succession planning process.공지 • Oct 13Tecan Reaffirms Earnings Guidance for the Year 2025Tecan reaffirmed earnings guidance for the year 2025. For the year, Tecan confirmed its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range. Tecan also reiterates its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. However, end markets are expected to recover gradually, so a full normalization is not anticipated in 2026. Guidance for 2026 will be provided, as usual, with the full-year 2025 results in March 2026.공지 • Oct 10Tecan Group AG to Report Fiscal Year 2025 Results on Mar 16, 2026Tecan Group AG announced that they will report fiscal year 2025 results on Mar 16, 2026공지 • Sep 13Tecan Group AG Announces Change of Leadership in the Partnering Business DivisionThe Tecan Group announced a change of leadership in its Partnering Business division. Ralf Griebel, who has served as Head of the Partnering Business division and as a member of the Management Board since April 2020, will be leaving the Company to pursue other opportunities. Monica Manotas will assume interim leadership of the Partnering Business division, taking this as an opportunity to work more closely with the business.공지 • Apr 04Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS.Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS on April 3, 2025. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits. To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits.공지 • Mar 24Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)공지 • Mar 19Tecan Group AG, Annual General Meeting, Apr 10, 2025Tecan Group AG, Annual General Meeting, Apr 10, 2025, at 15:00 W. Europe Standard Time.공지 • Mar 12+ 1 more updateTecan Group Ag Proposes Cash Dividend for the Year 2024Based on the solid cash flows for the full year 2024 and on the basis of an ongoing positive business outlook, the Board of Directors of Tecan Group AG will propose at the Company’s Annual General Meeting on April 18, 2025, an unchanged dividend of CHF 3.00 per share. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.공지 • Mar 06Tecan Group AG to Report Q4, 2024 Results on Jun 12, 2025Tecan Group AG announced that they will report Q4, 2024 results at 6:00 AM, Central European Standard Time on Jun 12, 2025공지 • Jan 28Tecan Introduces Veya: Bringing Digital, Scalable Automation to Labs WorldwideTecan announced the unveiling of Veya™, a transformative liquid handling platform designed to bring efficiency, precision and compliance to laboratories of all sizes. The platform, showcased at the Society for Laboratory Automation and Screening (SLAS) international conference, San Diego, underscores Tecan’s continued commitment to innovation and the democratization of lab automation. Veya overcomes key barriers in lab automation by offering an accessible and versatile platform that streamlines complex workflows and enables data-driven decision-making, while reducing downtime and enhancing productivity. Veya combines AI-enhanced automation, prebuilt workflows and an intuitive analytics interface, OneView™, to simplify complex tasks, including multiomics workflows. Its seamless integration with existing systems enables laboratories to boost productivity and meet important regulatory standards, including Europe’s CE-IVD and IVDR requirements. Key features of Veya: Simplified automation: Predeveloped workflows, intelligent analytics and a modular design boost productivity while reducing errors. Users report improvements of more than 60% in instrument utilization. High precision: Equipped with patented Air Restriction Pipetting (ARP), Veya handles volumes from 1 µl to 5 ml with precision. Real-time data: Improves decision-making and process optimization with live monitoring and actionable insights via a user-friendly interface. Continuous support: Features include 24-hour remote diagnostics, remote-guided troubleshooting and tailored service packages to minimize unplanned interruptions. Regulatory compliance: Veya is ideal for labs in regulated environments, ensuring compliance with key industry standards and regulatory requirements. Veya reflects Tecan’s commitment to democratize automation for laboratories of all sizes, including those constrained by budget or resources. By providing scalable, versatile and intuitive solutions for the ever-evolving needs of scientific research and diagnostics, Tecan continues to scale healthcare innovation globally.공지 • Dec 17Tecan Group AG to Report First Half, 2025 Results on Aug 12, 2025Tecan Group AG announced that they will report first half, 2025 results on Aug 12, 2025공지 • Aug 13+ 1 more updateTecan Group AG Revises Earnings Guidance for the Year 2024Tecan Group AG revised earnings guidance for the year 2024. Based on the financial results from the first half of the year, Tecan has revised its full-year outlook. This revision is also due to the anticipation that weaker demand, driven by general market weakness, will persist longer than originally expected, while the new China stimulus program is likely to have a meaningful impact only from 2025. The company now expects full-year 2024 sales in local currencies to range from on prior-year level to a decrease in the mid single-digit percentage range (previously expected to increase in the low single-digit percentage range in local currencies).공지 • Jun 25Tecan Appoints Mukta Acharya as Head of the Life Sciences Business Division, Effective from August 1, 2024Tecan Group AG announced that Mukta Acharya, currently serving as President, Tecan Americas, has been appointed the new Head of the Life Sciences Business division and a member of the Management Board of the Tecan Group. She is expected to assume her new position on August 1, 2024. Dr. Klaus Lun, Head of the Life Sciences Business since 2017 and a member of the Management Board since 2013, has decided to leave the company to pursue other career opportunities. Mukta Acharya joined Tecan in July 2022 as President, Tecan Americas, where she was responsible for the successful financial and market performance of the Life Sciences Business division in the company’s sales region. Mukta Acharya joined Tecan from Thermo Fisher Scientific, where she most recently served as Vice President and General Manager of the Single-use Flexible Solutions business. In this role, she drove the strategic growth of the global business, which spanned multiple manufacturing sites and thousands of employees worldwide. She also oversaw product management, marketing, engineering, and business development across the organization's various business units. From 2010 to 2018, Mukta Acharya held leadership positions at CVS Health, most recently as Director, Enterprise Product Innovation & Management. Prior to that, she worked in management consulting. She has a bachelor’s degree in Mechanical Engineering from India and a master’s degree in Engineering Management from Dartmouth College in the United States. Under Klaus Lun’s leadership, the Life Sciences Business division achieved significant growth and successfully navigated the challenges of the Covid-19 pandemic. Tecan’s Board of Directors and CEO would like to express their sincere gratitude to Klaus Lun for his strong engagement and important service of developing Tecan's Life Sciences Business and wish him all the best for the future.공지 • Apr 20Tecan Group Approves Dividend, Payable on April 24, 2024Tecan Group announced that at its AGM held on April 18, 2024, shareholders approved to an increase in the dividend from CHF 2.90 to CHF 3.00 per registered share. Half of the dividend, i.e., CHF 1.50, will be paid out from the available capital contribution reserve and is therefore not subject to withholding tax. The payout will take place on April 24, 2024.공지 • Apr 19Tecan Group Elects Monica Manotas as Additional Independent Member of the Board of DirectorsTecan Group announced that at its AGM held on April 18, 2024, the shareholders elected Monica Manotas as an additional independent member of the Tecan Board of Directors. With her many years of international experience in the life science industry and her proven expertise in finance, the industrial engineer with Colombian and US citizenship will strengthen the Board in a variety of ways.공지 • Mar 14+ 1 more updateTecan Group AG Provides Earnings Guidance for the Year 2024Tecan Group AG provided earnings guidance for the year 2024. For the year, the company expects Sales growth expected in the low single-digit percentage range in local currencies.공지 • Feb 06Tecan Group AG to Report First Half, 2024 Results on Aug 13, 2024Tecan Group AG announced that they will report first half, 2024 results on Aug 13, 2024공지 • Aug 17Tecan Group AG Provides Earnings Guidance for the Full Year 2023Tecan Group AG provided earnings guidance for the full year 2023. For the year, the company continues to forecast sales to increase in the low to mid single-digit percentage range in local currencies. This expectation includes the negative impact of lower COVID-related sales (approximately -4% points for the full year 2023, with the largest share of the impact already recorded in the first half of the year) and the reduced pass-through of material costs (at least -1% point). Underlying sales, which exclude these negative effects, are expected to grow in the high single-digit percentage range in local currencies.공지 • Aug 16Tecan Group AG to Report Fiscal Year 2023 Results on Mar 12, 2024Tecan Group AG announced that they will report fiscal year 2023 results on Mar 12, 2024공지 • Aug 15Tecan Group AG, Annual General Meeting, Apr 18, 2024Tecan Group AG, Annual General Meeting, Apr 18, 2024.공지 • Dec 08Tecan Group AG to Report First Half, 2023 Results on Aug 15, 2023Tecan Group AG announced that they will report first half, 2023 results on Aug 15, 2023공지 • Aug 17Tecan Group AG, Annual General Meeting, Apr 18, 2023Tecan Group AG, Annual General Meeting, Apr 18, 2023.이익 및 매출 성장 예측OTCPK:TCHB.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CHF Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20289818282141612/31/20279307173125812/31/20268844775132812/31/2025882-111103138N/A9/30/2025895-24118152N/A6/30/202590763134165N/A3/31/202592065126157N/A12/31/202493468118149N/A9/30/202496785105135N/A6/30/20241,00010193122N/A3/31/20241,037117109141N/A12/31/20231,074132126161N/A9/30/20231,088120114151N/A6/30/20231,102109101140N/A3/31/20231,12311597134N/A12/31/20221,14412192128N/A9/30/20221,11011391129N/A6/30/20221,07710589129N/A3/31/20221,012113110149N/A12/31/2021947122130170N/A9/30/2021911136163203N/A6/30/2021875150195237N/A3/31/2021803127181223N/A12/31/2020731104167208N/A9/30/202069194142177N/A6/30/202065184118146N/A3/31/20206447996122N/A12/31/2019637737599N/A9/30/201962770N/A95N/A6/30/201961667N/A90N/A3/31/201960569N/A92N/A12/31/201859471N/A93N/A9/30/201858270N/A99N/A6/30/201857069N/A106N/A3/31/201855967N/A103N/A12/31/201754966N/A99N/A9/30/201753662N/A93N/A6/30/201752357N/A86N/A3/31/201751556N/A102N/A12/31/201650655N/A119N/A9/30/201649155N/A124N/A6/30/201647655N/A129N/A3/31/201645856N/A114N/A12/31/201544057N/A99N/A9/30/201543452N/A83N/A6/30/201542748N/A67N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TCHB.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: TCHB.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: TCHB.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: TCHB.F 의 수익(연간 4.6%)이 US 시장(연간 11.4%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: TCHB.F 의 수익(연간 4.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: TCHB.F의 자본 수익률은 3년 후 8.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/06 14:04종가2026/04/17 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Tecan Group AG는 18명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Harry GillisBerenbergDelphine Le LouetBernsteinSusannah LudwigBernstein15명의 분석가 더 보기
공지 • Oct 13Tecan Reaffirms Earnings Guidance for the Year 2025Tecan reaffirmed earnings guidance for the year 2025. For the year, Tecan confirmed its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range. Tecan also reiterates its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. However, end markets are expected to recover gradually, so a full normalization is not anticipated in 2026. Guidance for 2026 will be provided, as usual, with the full-year 2025 results in March 2026.
공지 • Aug 13+ 1 more updateTecan Group AG Revises Earnings Guidance for the Year 2024Tecan Group AG revised earnings guidance for the year 2024. Based on the financial results from the first half of the year, Tecan has revised its full-year outlook. This revision is also due to the anticipation that weaker demand, driven by general market weakness, will persist longer than originally expected, while the new China stimulus program is likely to have a meaningful impact only from 2025. The company now expects full-year 2024 sales in local currencies to range from on prior-year level to a decrease in the mid single-digit percentage range (previously expected to increase in the low single-digit percentage range in local currencies).
공지 • Mar 14+ 1 more updateTecan Group AG Provides Earnings Guidance for the Year 2024Tecan Group AG provided earnings guidance for the year 2024. For the year, the company expects Sales growth expected in the low single-digit percentage range in local currencies.
공지 • Aug 17Tecan Group AG Provides Earnings Guidance for the Full Year 2023Tecan Group AG provided earnings guidance for the full year 2023. For the year, the company continues to forecast sales to increase in the low to mid single-digit percentage range in local currencies. This expectation includes the negative impact of lower COVID-related sales (approximately -4% points for the full year 2023, with the largest share of the impact already recorded in the first half of the year) and the reduced pass-through of material costs (at least -1% point). Underlying sales, which exclude these negative effects, are expected to grow in the high single-digit percentage range in local currencies.
공지 • Apr 16Tecan Group Ag Announces Executive ChangesTecan Group AG in its AGM meeting held on April 15, 2026, announced that shareholders elected three new members of the Board of Directors: Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot. Matthias Gillner, who has been a member of the Board of Directors since 2023 and its Vice-Chairman, was elected as the new Chairman. He will step down as Chair of the Audit Committee but will remain a member, alongside Guillaume Daniellot and Gitte Pugholm Aabo. With the addition of the newly elected members, the Board of Directors will once again comprise seven members, ensuring an optimal balance of expertise, skills, and experience for the future. Lukas Braunschweiler, Chairman and a member of the Board since 2018, did not stand for re-election.
공지 • Mar 30The Tecan Group Announces the Appointment of Camila Japur as Chief Financial Officer, Effective on June 1, 2026The Tecan Group announced the appointment of Camila Japur as Chief Financial Officer, who will join the company on June 1, 2026. Camila currently serves as Group CFO of u-blox, where she has successfully led transformation initiatives, driving cost efficiency, strengthening financial processes, and enhancing capital market engagement. Prior to this, Camila spent 24 years at Ericsson, including seven years as CFO for the Enterprise Segment. Camila has an MBA from Fundação Getulio Vargas in São Paulo and a Bachelor's Degree in Economics from Universidade Mackenzie in São Paulo.
공지 • Mar 25Tecan Group AG Announces Member of the Board of Directors Oliver Fetzer Will Not Stand for Re-ElectionTecan Group AG announced that Oliver Fetzer, a member of the Board since 2011, has decided not to stand for re-election at the AGM to be held on April 15, 2026.
공지 • Mar 16+ 1 more updateTecan Group AG Proposes Dividend for the Full Year 2025The Board of Directors of Tecan Group AG will propose an unchanged dividend of CHF 3.00 per share at the Annual General Meeting on April 15, 2026 for the full year 2025. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.
공지 • Dec 19Tecan Group AG to Report First Half, 2026 Results on Aug 11, 2026Tecan Group AG announced that they will report first half, 2026 results on Aug 11, 2026
공지 • Dec 05Tecan Group AG, Annual General Meeting, Apr 15, 2026Tecan Group AG, Annual General Meeting, Apr 15, 2026.
공지 • Dec 04ecan Group AG Announces Chairman of the Board of Directors Lukas Braunschweiler Will Not Stand for Re-ElectionTecan Group AG announced that Lukas Braunschweiler, Chairman of the Board of Directors and a member of the Board since 2018, will not stand for re-election.
공지 • Dec 02Tecan Group AG (SWX:TECN) acquired Wako Automation.Tecan Group AG (SWX:TECN) acquired Wako Automation on December 1, 2025. Tecan Group AG (SWX:TECN) completed the acquisition of Wako Automation on December 1, 2025.
공지 • Nov 17+ 1 more updateTecan Group AG Announces Departure of Tania Micki as Member of the Management BoardTecan Group AG announced that Tania Micki, member of the Management Board since February 2020, will be leaving the company to pursue an external opportunity. She will continue in her role through May 2026 to ensure a smooth transition. Tecan will nominate her successor in due time, leveraging the company’s succession planning process.
공지 • Oct 13Tecan Reaffirms Earnings Guidance for the Year 2025Tecan reaffirmed earnings guidance for the year 2025. For the year, Tecan confirmed its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range. Tecan also reiterates its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. However, end markets are expected to recover gradually, so a full normalization is not anticipated in 2026. Guidance for 2026 will be provided, as usual, with the full-year 2025 results in March 2026.
공지 • Oct 10Tecan Group AG to Report Fiscal Year 2025 Results on Mar 16, 2026Tecan Group AG announced that they will report fiscal year 2025 results on Mar 16, 2026
공지 • Sep 13Tecan Group AG Announces Change of Leadership in the Partnering Business DivisionThe Tecan Group announced a change of leadership in its Partnering Business division. Ralf Griebel, who has served as Head of the Partnering Business division and as a member of the Management Board since April 2020, will be leaving the Company to pursue other opportunities. Monica Manotas will assume interim leadership of the Partnering Business division, taking this as an opportunity to work more closely with the business.
공지 • Apr 04Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS.Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS on April 3, 2025. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits. To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits.
공지 • Mar 24Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)
공지 • Mar 19Tecan Group AG, Annual General Meeting, Apr 10, 2025Tecan Group AG, Annual General Meeting, Apr 10, 2025, at 15:00 W. Europe Standard Time.
공지 • Mar 12+ 1 more updateTecan Group Ag Proposes Cash Dividend for the Year 2024Based on the solid cash flows for the full year 2024 and on the basis of an ongoing positive business outlook, the Board of Directors of Tecan Group AG will propose at the Company’s Annual General Meeting on April 18, 2025, an unchanged dividend of CHF 3.00 per share. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.
공지 • Mar 06Tecan Group AG to Report Q4, 2024 Results on Jun 12, 2025Tecan Group AG announced that they will report Q4, 2024 results at 6:00 AM, Central European Standard Time on Jun 12, 2025
공지 • Jan 28Tecan Introduces Veya: Bringing Digital, Scalable Automation to Labs WorldwideTecan announced the unveiling of Veya™, a transformative liquid handling platform designed to bring efficiency, precision and compliance to laboratories of all sizes. The platform, showcased at the Society for Laboratory Automation and Screening (SLAS) international conference, San Diego, underscores Tecan’s continued commitment to innovation and the democratization of lab automation. Veya overcomes key barriers in lab automation by offering an accessible and versatile platform that streamlines complex workflows and enables data-driven decision-making, while reducing downtime and enhancing productivity. Veya combines AI-enhanced automation, prebuilt workflows and an intuitive analytics interface, OneView™, to simplify complex tasks, including multiomics workflows. Its seamless integration with existing systems enables laboratories to boost productivity and meet important regulatory standards, including Europe’s CE-IVD and IVDR requirements. Key features of Veya: Simplified automation: Predeveloped workflows, intelligent analytics and a modular design boost productivity while reducing errors. Users report improvements of more than 60% in instrument utilization. High precision: Equipped with patented Air Restriction Pipetting (ARP), Veya handles volumes from 1 µl to 5 ml with precision. Real-time data: Improves decision-making and process optimization with live monitoring and actionable insights via a user-friendly interface. Continuous support: Features include 24-hour remote diagnostics, remote-guided troubleshooting and tailored service packages to minimize unplanned interruptions. Regulatory compliance: Veya is ideal for labs in regulated environments, ensuring compliance with key industry standards and regulatory requirements. Veya reflects Tecan’s commitment to democratize automation for laboratories of all sizes, including those constrained by budget or resources. By providing scalable, versatile and intuitive solutions for the ever-evolving needs of scientific research and diagnostics, Tecan continues to scale healthcare innovation globally.
공지 • Dec 17Tecan Group AG to Report First Half, 2025 Results on Aug 12, 2025Tecan Group AG announced that they will report first half, 2025 results on Aug 12, 2025
공지 • Aug 13+ 1 more updateTecan Group AG Revises Earnings Guidance for the Year 2024Tecan Group AG revised earnings guidance for the year 2024. Based on the financial results from the first half of the year, Tecan has revised its full-year outlook. This revision is also due to the anticipation that weaker demand, driven by general market weakness, will persist longer than originally expected, while the new China stimulus program is likely to have a meaningful impact only from 2025. The company now expects full-year 2024 sales in local currencies to range from on prior-year level to a decrease in the mid single-digit percentage range (previously expected to increase in the low single-digit percentage range in local currencies).
공지 • Jun 25Tecan Appoints Mukta Acharya as Head of the Life Sciences Business Division, Effective from August 1, 2024Tecan Group AG announced that Mukta Acharya, currently serving as President, Tecan Americas, has been appointed the new Head of the Life Sciences Business division and a member of the Management Board of the Tecan Group. She is expected to assume her new position on August 1, 2024. Dr. Klaus Lun, Head of the Life Sciences Business since 2017 and a member of the Management Board since 2013, has decided to leave the company to pursue other career opportunities. Mukta Acharya joined Tecan in July 2022 as President, Tecan Americas, where she was responsible for the successful financial and market performance of the Life Sciences Business division in the company’s sales region. Mukta Acharya joined Tecan from Thermo Fisher Scientific, where she most recently served as Vice President and General Manager of the Single-use Flexible Solutions business. In this role, she drove the strategic growth of the global business, which spanned multiple manufacturing sites and thousands of employees worldwide. She also oversaw product management, marketing, engineering, and business development across the organization's various business units. From 2010 to 2018, Mukta Acharya held leadership positions at CVS Health, most recently as Director, Enterprise Product Innovation & Management. Prior to that, she worked in management consulting. She has a bachelor’s degree in Mechanical Engineering from India and a master’s degree in Engineering Management from Dartmouth College in the United States. Under Klaus Lun’s leadership, the Life Sciences Business division achieved significant growth and successfully navigated the challenges of the Covid-19 pandemic. Tecan’s Board of Directors and CEO would like to express their sincere gratitude to Klaus Lun for his strong engagement and important service of developing Tecan's Life Sciences Business and wish him all the best for the future.
공지 • Apr 20Tecan Group Approves Dividend, Payable on April 24, 2024Tecan Group announced that at its AGM held on April 18, 2024, shareholders approved to an increase in the dividend from CHF 2.90 to CHF 3.00 per registered share. Half of the dividend, i.e., CHF 1.50, will be paid out from the available capital contribution reserve and is therefore not subject to withholding tax. The payout will take place on April 24, 2024.
공지 • Apr 19Tecan Group Elects Monica Manotas as Additional Independent Member of the Board of DirectorsTecan Group announced that at its AGM held on April 18, 2024, the shareholders elected Monica Manotas as an additional independent member of the Tecan Board of Directors. With her many years of international experience in the life science industry and her proven expertise in finance, the industrial engineer with Colombian and US citizenship will strengthen the Board in a variety of ways.
공지 • Mar 14+ 1 more updateTecan Group AG Provides Earnings Guidance for the Year 2024Tecan Group AG provided earnings guidance for the year 2024. For the year, the company expects Sales growth expected in the low single-digit percentage range in local currencies.
공지 • Feb 06Tecan Group AG to Report First Half, 2024 Results on Aug 13, 2024Tecan Group AG announced that they will report first half, 2024 results on Aug 13, 2024
공지 • Aug 17Tecan Group AG Provides Earnings Guidance for the Full Year 2023Tecan Group AG provided earnings guidance for the full year 2023. For the year, the company continues to forecast sales to increase in the low to mid single-digit percentage range in local currencies. This expectation includes the negative impact of lower COVID-related sales (approximately -4% points for the full year 2023, with the largest share of the impact already recorded in the first half of the year) and the reduced pass-through of material costs (at least -1% point). Underlying sales, which exclude these negative effects, are expected to grow in the high single-digit percentage range in local currencies.
공지 • Aug 16Tecan Group AG to Report Fiscal Year 2023 Results on Mar 12, 2024Tecan Group AG announced that they will report fiscal year 2023 results on Mar 12, 2024
공지 • Aug 15Tecan Group AG, Annual General Meeting, Apr 18, 2024Tecan Group AG, Annual General Meeting, Apr 18, 2024.
공지 • Dec 08Tecan Group AG to Report First Half, 2023 Results on Aug 15, 2023Tecan Group AG announced that they will report first half, 2023 results on Aug 15, 2023
공지 • Aug 17Tecan Group AG, Annual General Meeting, Apr 18, 2023Tecan Group AG, Annual General Meeting, Apr 18, 2023.